IVA

Inventiva S.A. (NASDAQ:IVA) is a French clinical-stage biopharmaceutical company founded in 2011 and headquartered in Daix, France. The company went public on NASDAQ in July 2020, focusing on developing oral small molecule therapies for serious diseases with significant unmet medical needs. Inventiva has evolved from a multi-program biotech into a focused developer of treatments for metabolic and rare diseases, with its lead candidate lanifibranor currently in Phase 3 clinical trials for MASH (metabolic dysfunction-associated steatohepatitis), formerly known as NASH (non-alcoholic steatohepatitis).